Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
January 2018
-
Media ReleaseNovartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**SURPASS is the first head-to-head superiority trial versus proposed biosimilar adalimumab** in ankylosing spondylitis (AS)[1] EXCEED is the first head-to-head superiority trial…
-
Media ReleaseREGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular AtrophyAveXis acquires exclusive rights to entire NAV Technology Platform for the development of treatments for SMA Amended agreement permits assignment by AveXis upon a change of control…
-
Organic dealmaker for drug discovery
New Global Head of Business Development and Licensing for research makes connections naturally, decisions scientifically.
-
Open science demystified
Jay Bradner discusses his vision for an open framework of scientific discovery at Novartis.
-
Media ReleaseAveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1– Company to submit information requested by FDA to the IND on an on-going basis – – AveXis plans to request a pre-BLA meeting in Q2 2018 – – Conference call and webcast today at 4:…
-
Media ReleaseNovartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)Data supporting designation showed over half of treatment-naïve SAA patients achieved complete response with Promacta when given with standard immunosuppressive therapy, with overall response rate of…
-
Media ReleaseNovartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancerDesignation based on Phase III MONALEESA-7 results demonstrating superior efficacy of Kisqali in combination with oral endocrine therapy compared to oral endocrine therapy in pre- or perimenopausal…
December 2017
-
Media ReleaseNovartis drug Tasigna® is approved by FDA as first and only CML therapy with Treatment-free Remission data in its labelInclusion of Treatment-free Remission (TFR) data provides additional and novel option in management of Ph+ CML-CP Deep and sustained molecular response included as key eligibility criteria…
-
Media ReleaseNovartis' combination therapy Tafinlar® + Mekinist® granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanomaPriority Review designation based on Phase III study showing 53% reduction in risk of recurrence or death with Tafinlar + Mekinist, as compared to placebo[1] Improvements observed in key…
-
Media ReleaseNovartis announces Oncology head to retireBasel, December 15, 2017 - Novartis announced today that Bruno Strigini, CEO Novartis Oncology has decided to retire from Novartis and the industry for personal reasons. Joseph Jimenez, CEO of…
-
Media ReleaseNovartis gibt Rücktritt des Onkologie-Chefs bekanntBasel, 15. Dezember 2017 - Novartis gibt bekannt, dass sich Bruno Strigini, CEO Novartis Onkologie, entschieden hat, die Firma aus persönlichen Gründen zu verlassen und sich aus der Industrie…
-
Media ReleaseNovartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN studyInvestigational therapy crizanlizumab (SEG101, formerly SelG1) approximately doubled the time to first on-treatment sickle cell pain crisis, according to new subgroup analysis of Phase II SUSTAIN…
Pagination
- ‹ Previous page
- 1
- …
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- …
- 152
- › Next page